DAE HWA Pharmaceutical Co., Ltd.
Financials
Valuation Metrics
DAE HWA Pharmaceutical Co., Ltd.'s Market Cap is ₩1674B. At end of 2025 it was ₩3245B. Ranked #894 of 2,405 in KR market (top 37%), #416 of 1,627 on KOSDAQ (top 26%), #102 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 44%) by Market Cap.
Investment Metrics(as of 2026-11-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 167.36B KRW | KR#894/2,405 Sec#102/231 |
| Revenue | 148.75B KRW | KR#1,187/2,405 Sec#71/231 |
| Net Income | 4.86B KRW | KR#1,227/2,405 Sec#83/231 |
| Total Assets | 220.34B KRW | KR#1,244/2,405 Sec#90/231 |
| Net Assets | 85.72B KRW | KR#1,528/2,405 Sec#121/231 |
| Employees | 365 | KR#663/2,405 Sec#58/231 |
| Value | ||
| P/E | 34.42x | KR#1,360/2,405 Sec#85/231 |
| P/B | 1.95x | KR#1,985/2,405 Sec#149/231 |
| PEG | 0.23x | KR#609/2,405 Sec#36/231 |
| P/S | 1.13x | KR#1,527/2,405 Sec#87/231 |
| EV/EBITDA | 48.25x | KR#1,355/2,405 Sec#88/231 |
| FCF Yield | 3.21% | KR#994/2,405 Sec#61/231 |
| Profitability | ||
| ROE | 5.67% | KR#1,017/2,405 Sec#70/231 |
| ROA | 2.21% | KR#1,178/2,405 Sec#88/231 |
| Op. Margin | 3.72% | KR#1,132/2,405 Sec#81/231 |
| Revenue Growth | 0.14% | KR#1,514/2,405 Sec#152/231 |
| Earnings Growth | 147.12% | KR#314/2,405 Sec#18/231 |
| Financial Health | ||
| Debt Ratio | 157.03% | KR#1,935/2,405 Sec#209/231 |
| Total Debt | 101.61B KRW | KR#718/2,405 Sec#45/231 |
| FCF | 5.38B KRW | KR#882/2,405 Sec#61/231 |
| Cash | 2.15B KRW | KR#2,231/2,405 Sec#213/231 |
| Current Ratio | 0.56x | KR#2,096/2,405 Sec#201/231 |
| Net Debt/EBITDA | 17.98x | KR#1,351/2,405 Sec#97/231 |
| Dividend | ||
| Div. Yield | 1.62% | KR#1,005/2,405 Sec#55/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -46.52% | KR#1,864/2,405 Sec#158/231 |
| 1M Return | -22.57% | KR#1,895/2,405 Sec#185/231 |
| From 52W High | -63.90% | KR#1,792/2,405 Sec#150/231 |
| 1Y MDD | -66.22% | KR#1,779/2,405 Sec#152/231 |
| Trading | ||
| Volume | 19,904 shares | KR#1,420/2,405 Sec#138/231 |
| Trading Value | 180.8M KRW | KR#1,120/2,405 Sec#126/231 |
| Foreign Own. | 0.47% | KR#2,203/2,405 Sec#213/231 |
| Per Share | ||
| EPS | 261 KRW | KR#1,208/2,405 Sec#84/231 |
| BPS | 4,605 KRW | KR#1,564/2,405 Sec#114/231 |
Company Info
Established in 1984 and listed on KOSDAQ in 2003, Daehwa Pharmaceutical is an innovative pharmaceutical company with 5 subsidiaries, including 3 domestic and 2 overseas. It engages in pharmaceutical manufacturing, wholesale, medical information systems, and the manufacturing and sales of pharmaceutical raw materials, cosmetics, and medical devices. The company produces treatments for infectious and digestive diseases at its GMP-certified factories, capturing 65% of the domestic OEM market. Daehwa Pharmaceutical is headquartered in Hoengseong-gun, Gangwon-do.